Invest in your brain health

Play a part in developing predictive algorithms for epilepsy, Alzheimer’s, and Parkinson’s disease.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For risks relating to this offering, see the Subscription Agreement for this offering.
The Importance of Sanitary, Disposable NeuroCap
A recent report indicated that more than one-third of coronavirus patients had some type of neurologic symptom. Neurologists and other medical practitioners are urged to follow sanitary techniques to avoid spreading COVID-19 through cross-contamination.

We believe that disposable EEG headset NeuroCap can help flatten the Covid-19 curve.
Why Invest?
Brain Scientific’s mission is to develop algorithms to detect neurological disorders, including epilepsy, memory dementia, and pre-Alzheimer’s diagnosis.
Neurological disorders are increasingly recognized as major causes of death and disability worldwide. More than 50 million people have epilepsy worldwide.
It is estimated that this number will almost double
World Health Organization, 2020
Our first commercialized products, NeuroCap and NeuroEEG, aim to disrupt the expensive EEG market with economic and disposable substitutes that permit any medical professional in any setting to diagnose patients remotely within minutes.
We want to improve patient access to neurological care and provide analysis through artificial intelligence (AI) to improve diagnosis. To achieve this, we plan 
to create a database of normal and abnormal brains for detecting seizures and dementia, and AI and machine learning processes will help detect
abnormal activity.
Market Demand
The brain monitoring industry is composed of smaller markets that aim to understand, diagnose, treat, and cure mental conditions. These emerging industries account for a majority of the growth in the brain monitoring industry, and drive the need for improved brain monitoring technology.
Neurological Condition and Number
of Diagnosed Individuals
Alzheimer’s disease
40 million
Sports-related head injuries
446,788 (US Only)
350 million
50 million
6.4 million
795,000 (per year)
Sleep disorders
150 million
47.5 million
37 million
Here is
the math
Someone in the world develops
dementia every 3 seconds.
It is estimated that globally there are 47.5
million people with dementia, with 7.7
million new cases every year. Alzheimer's
disease is the most common cause of
dementia and may contribute to 60–70%
of cases.
Around 50 million
people worldwide  have epilepsy,
making it one of the most
common neurological
diseases globally.
Nearly 80% of people with epilepsy live in
low- and middle-income countries. It is
estimated that up to 70% of people living
with epilepsy could live seizure-free if
properly diagnosed and treated.
About 1% of Americans
have some form
of epilepsy, and nearly
4% (1 in 26) will develop
epilepsy at some point in
their lives.
The number of Americans who have
epilepsy is greater than the number
who have multiple sclerosis, Parkinson's
disease, and cerebral palsy combined.
  • Brain Scientific has developed two EEG devices to streamline EEG application and diagnosis:
    NeuroCap, a disposable EEG headset with 22 pre-gelled electrodes following the international 10–20 system, and NeuroEEG, a portable wireless EEG amplifier that is smaller than a deck of playing cards.
  • Brain Scientific has received FDA 510(k) clearance for NeuroCap and NeuroEEG in 2018
  • Successful early adopters program for NeuroCap and NeuroEEG (2018—2019)
  • Partner with industry leaders in EEG manufacturing and distributors to service national and global EEG market in progress
  • In 2018—2019, Brain Scientific has presented the company’s technology and devices at international and American conferences and trade shows
    including American Epilepsy Society (AES) Annual meetings, ASET, ACNS.
Brain Scientific’s project on graphene EEG electrodes was chosen by Epilepsy Foundation for 2020 Shark Tank Competition Five Finalists
Shark Tank Competition
Our products are already operating across the
country and have received good reviews
Product Roadmap
We are constantly working on new products to address new, growing markets.
Developing product line extensions address new,
growing markets: Pediatric and Long-Term Monitoring.
1. Routine EEG
New product for Routine market:
NeuroCap-8 (with 8 channels)
2. Pediatric EEG Caps
New product for Routine market:
NeuroCap-8 Pediatric
3. Long -Term Monitoring
New products for LTM market (24+ hours):
NeuroCap-8 Adult, NeuroCap-19 Adult,
NeuroCap-8 Pediatric, NeuroEEG
Amplifier(24 channels)
4. Artificial Intelligence
New products for AI market: Brain
E-Tattoo, Brain AI: Neutral Network
enabled predictive capabilities for brain
health / disease progression